[{"ID":"35384_75-2021_NCT00865371","TOPIC_YEAR":2021,"RESPONSE":"#1: Is the patient a healthy, normal adult man who volunteers to participate?\nNo, the patient is not a healthy, normal adult man. The patient has Parkinson's disease, which is a neurological disorder.\n\n#2: Is he 18-45 years of age, inclusive?\nNo, the patient is 55 years old, which is outside the age range of 18-45.\n\n#3: Is his BMI \u226430?\nNo, the patient's BMI is not provided, but based on his age and health status, it is likely to be higher than 30.\n\n#4: Is he considered reliable and capable of understanding his responsibility and role in the study?\nNo, the patient has a neurological disorder and may not be reliable or capable of understanding the study.\n\n#5: Has he provided written informed consent?\nNo, the patient is not eligible for the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9346836859},{"ID":"28014_40-2022_NCT04053699","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is a female with VWD.\n\n#2: The patient is currently receiving on-demand treatment with a VWF-containing product.\n\n#3: The patient meets all the inclusion criteria.\n\n#4: The patient does not meet any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.8820169259},{"ID":"30398_65-2021_NCT00125437","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have nonischemic cardiomyopathy?\nYes, the patient has nonischemic cardiomyopathy.\n\n#2: Does the patient have a left ventricular ejection fraction (LVEF) of less than 35%?\nYes, the patient has a LVEF of less than 35%.\n\n#3: Is the patient's renal function preserved?\nYes, the patient's renal function is preserved.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9394099134},{"ID":"25078_53-2021_NCT01402115","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have reduced bone density but no evidence of osteoporosis or osteopenia by DEXA scan (T \u2265 -1.0 in the lumbar spine)?\nNo, the patient does not meet this criterion.\n\n#2: Is the patient a perimenopausal woman aged 40-70?\nYes, the patient is a perimenopausal woman.\n\n#3: Does the patient have any significant illness affecting bone metabolism?\nNo, the patient does not have any significant illness affecting bone metabolism.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.94360516},{"ID":"5309_12-2021_NCT01621971","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan's syndrome, which is a genetic disorder that affects the body's connective tissue. The patient also has severe mitral valve prolapse with regurgitation, which is a condition that can be associated with Marfan's syndrome.\n\nThe clinical trial is investigating the effects of inhaled milrinone on pulmonary arterial pressure before cardiopulmonary bypass in patients undergoing mitral valve surgery. The trial is specifically looking at patients with severe mitral regurgitation, which the patient has.\n\nThe patient has agreed to participate in the study and has signed written informed consent, which meets the inclusion criteria for the trial.\n\nHowever, the patient has a history of gestational diabetes mellitus, hypertension during pregnancy, and obesity, which are not specified as exclusion criteria in the trial. The patient also had laser eye surgery, cataract surgery, and foot surgery, but these are not relevant to the current trial.\n\nTherefore, the patient is eligible for the clinical trial.\n\nA: eligible","PROBA":0.9178598157},{"ID":"18652_27-2022_NCT00005657","TOPIC_YEAR":2022,"RESPONSE":"#1 The patient has a completely different medical condition than the clinical trial. The patient has Lyme disease, and the clinical trial is for Hepatitis C.\n\n#2 The patient is not an adult, so they would be excluded from the clinical trial based on the exclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.8555859255},{"ID":"35639_75-2021_NCT03301272","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 55 years old, which is within the inclusion criteria age range of 45-80 years old.\n\n#2: Diagnosis\nThe patient has been diagnosed with Parkinson's disease, which is an inclusion criterion for the clinical trial.\n\n#3: Rest tremor\nThe patient has rest tremor, which is an inclusion criterion for the clinical trial.\n\n#4: Medication history\nThe patient has a history of taking levodopa and trihexyphenidyl, which are typical anti-parkinsonian agents. This meets the inclusion criterion of having tried at least two categories of medications.\n\n#5: Ability to remain on current medications\nThe patient is able to remain on their current medications for the duration of the study, which meets the inclusion criterion.\n\n#6: No previous botulinum toxin injections\nThe patient has not had any previous botulinum toxin injections, which meets the exclusion criterion.\n\n#7: No allergies to study medications\nThe patient does not have any allergies to the study medications, which meets the exclusion criterion.\n\n#8: No muscle weakness\nThe patient does not have muscle weakness, which meets the exclusion criterion.\n\n#9: No pre-existing neuromuscular disorder\nThe patient does not have a pre-existing neuromuscular disorder, which meets the exclusion criterion.\n\n#10: No compromised respiratory function\nThe patient does not have compromised respiratory function, which meets the exclusion criterion.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9409671991},{"ID":"35828_75-2021_NCT04821830","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Is the patient's disease stage mild to moderate (Hoehn & Yahr Stages I-II)?\nYes, the patient's disease stage is mild (Hoehn-Yahr Stage I).\n\n#3: Is the patient about to start treatment with a L-Dopa preparation (Sinemet)?\nYes, the patient has been offered Levodopa and Trihexyphenidyl.\n\n#4: Does the patient have any exclusion criteria (depression, stroke, cognitive impairment, etc.)?\nNo, the patient does not have any exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9533288479},{"ID":"35538_75-2021_NCT02370134","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is an adult (age 18 or older).\n#2: The patient has Parkinson's disease.\n#3: The patient has a predominantly rest tremor that is intractable to medical treatment.\n\nYes, the patient is eligible for the clinical trial.","PROBA":0.8832187078},{"ID":"35697_75-2021_NCT03808675","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is a male.\n\n#2: The patient is aged 40 or older.\n\n#3: The patient has a diagnosis of idiopathic Parkinson's disease.\n\n#4: The patient is on a stable dopaminergic treatment regimen for at least 4 weeks prior to baseline.\n\n#5: The patient has a VO2max below \"very good\" fitness levels for their age and gender.\n\n#6: The patient does not have dementia per Movement Disorder Society Level I criteria.\n\n#7: The patient is currently active in driving.\n\n#8: The patient does not have any confounding acute or unstable medical, psychiatric, or orthopedic conditions.\n\nBased on the information provided, the patient is eligible for the clinical trial.","PROBA":0.9349241762},{"ID":"35511_75-2021_NCT02037451","TOPIC_YEAR":2021,"RESPONSE":"#1: Clinical diagnosis of Parkinson disease\n\nYes, the patient has a clinical diagnosis of Parkinson's disease, so this criterion is met.\n\n#2: No other neurological diseases\n\nThe patient does not have any other neurological diseases, so this criterion is met.\n\n#3: No dementia\n\nThe patient does not have dementia, so this criterion is met.\n\n#4: No history of seizures\n\nThe patient does not have a history of seizures, so this criterion is met.\n\n#5: No brain trauma\n\nThe patient does not have a history of brain trauma, so this criterion is met.\n\n#6: No body with a pacemaker or other electrical stimulator\n\nThe patient does not have a pacemaker or other electrical stimulator, so this criterion is met.\n\n#7: Not pregnant\n\nThe patient is not pregnant, so this criterion is met.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9653818335},{"ID":"14149_30-2021_NCT03097237","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a BMI of 27-35 kg\/m2?\nYes, the patient has a BMI of 31, which is within the inclusion criteria range of 27-35 kg\/m2.\n\n#2: Is the patient's serum TSH level \u22644.00 mIU\/L?\nNo, the patient's serum TSH level is 13 mU\/L, which is outside the inclusion criteria range of \u22644.00 mIU\/L.\n\n#3: Does the patient have any of the exclusion criteria?\nYes, the patient has a thyroid disorder (Hashimoto's thyroiditis), which is an exclusion criterion.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9496032871},{"ID":"6765_15-2021_NCT01897623","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have coronary artery disease?\nNo, the patient does not have coronary artery disease. The patient has a history of CAD, but it is not currently mentioned as a diagnosis.\n\n#2: Is the patient male?\nYes, the patient is male.\n\n#3: Is the patient willing to participate in the study?\nNo, the patient is not willing to participate in the study because they do not meet the inclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9041988277},{"ID":"35774_75-2021_NCT04308135","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Does the patient meet the inclusion criteria for the clinical trial?\nYes, the patient meets the inclusion criteria for the clinical trial, which includes patients diagnosed with Parkinson's disease or vascular parkinsonism.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9241611406},{"ID":"23470_33-2022_NCT03059043","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have myopia?\nYes, the patient has myopia.\n\n#2: Is the patient's myopia within the range of -0.5D to -18.0D?\nYes, the patient's myopia is within the range of -0.5D to -18.0D.\n\n#3: Is the patient willing to undergo ICL implantation?\nYes, the patient is cooperative with medical appointments.\n\n#4: Does the patient meet the inclusion criteria for the study?\nYes, the patient meets all the inclusion criteria for the study.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9308277061},{"ID":"13938_30-2021_NCT00271427","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have AIT (Autoimmune Thyroiditis)?\nYes, the patient has been diagnosed with Hashimoto's thyroiditis, which is a type of AIT.\n\n#2: Is the patient taking only LT4 to keep TSH in the lower half of the normal range?\nYes, the patient is taking 250 mcg Levothyroxine per day, which is a form of LT4.\n\n#3: Is the patient excluded from the clinical trial due to any other medication use or known pathology that may affect GIS absorption?\nNo, the patient is not excluded from the clinical trial based on the listed exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9338577539},{"ID":"5545_12-2021_NCT04527367","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan's syndrome, which is a genetic disorder that affects the body's connective tissue. The patient has mitral valve prolapse with severe mitral regurgitation, which is a common complication of Marfan's syndrome.\n\nThe clinical trial is focused on patients with valvular heart disease in moderate and severe stages. The patient's mitral valve prolapse with severe mitral regurgitation meets the inclusion criteria for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the answer is: A: eligible","PROBA":0.9215974049},{"ID":"27645_40-2022_NCT01526915","TOPIC_YEAR":2022,"RESPONSE":"# No, the patient is not eligible for the clinical trial.\n\nThe patient has prolonged oral bleeding after a tooth extraction, which is not related to bisphosphonates or jawbone osteochemonecrosis. The clinical trial is focused on the use of platelet-rich fibrin (PRF) to prevent healing delay and jawbone osteochemonecrosis in patients who have undergone tooth extraction and have a history of bisphosphonate use. The patient does not meet the inclusion criteria for the clinical trial, as they do not have a history of bisphosphonate use and do not have jawbone osteochemonecrosis. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9352786096},{"ID":"27964_40-2022_NCT03751800","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is a woman.\n\nYes, the patient is a woman, which meets the inclusion criterion of being a woman aged 18 or older who is not intending to become pregnant during the next year.\n\n#2: The patient has heavy menstrual bleeding.\n\nYes, the patient has heavy menstrual bleeding, which meets the inclusion criterion of being diagnosed with heavy menstrual bleeding or idiopathic menorrhagia according to medical criteria and based on clinical judgment.\n\n#3: The patient is willing to receive chronic hormonal treatment.\n\nYes, the patient is willing to receive chronic hormonal treatment, which meets the inclusion criterion of being willing to receive any of the available chronic hormonal treatments with the therapeutic indication of HMB in Spain (Mirena, Qlaira, or Progevera).\n\n#4: The patient is capable of reading and writing.\n\nYes, the patient is capable of reading and writing, which meets the inclusion criterion of being capable of reading and writing.\n\n#5: The patient has signed the informed consent.\n\nYes, the patient has signed the informed consent, which meets the inclusion criterion of having signed the informed consent.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9557941504},{"ID":"33481_71-2021_NCT00909766","TOPIC_YEAR":2021,"RESPONSE":"#1: Obese subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations\n\nYes, the patient is obese and has a BMI of 41.54, which is well above the inclusion criteria range of 30 to 40 kg\/m\u00b2.\n\n#2: Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 55, inclusive\n\nThe patient is a woman, but she is not of childbearing potential due to her age (34) being outside the inclusion criteria range of 18 to 55. Therefore, she meets this criterion.\n\n#3: Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population\n\nThere is no evidence of organ dysfunction or any clinically significant deviation from normal in the patient's medical history, physical examination, ECGs, or clinical laboratory determinations.\n\n#4: Abnormal blood work results (for example, triglyceride \u2265 400 mg\/dL, glucose \u2265126 mg\/dL and total cholesterol \u2265 300 mg\/dL)\n\nThe patient's blood work results show elevated triglycerides (150 mg\/dL), glucose (100 mg\/dL), and total cholesterol (180 mg\/dL), which meet the inclusion criteria.\n\n#5: High blood pressure (\u2265160\/95 mm Hg)\n\nThe patient's blood pressure is not reported as being high, so this criterion is not met.\n\n#6: Major surgical procedure within 4 weeks prior to randomization\n\nThere is no mention of any recent surgical procedures, so this criterion is not met.\n\n#7: Chronic infections (e.g., HIV [human immunodeficiency virus] or Hepatitis C)\n\nThere is no mention of any chronic infections, so this criterion is not met.\n\n#8: Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease, or a previous surgery for weight loss\n\nThe patient has a history of sleep apnea and dissatisfaction with her body shape, but there is no mention of any other clinically significant conditions.\n\n#9: History of gastrointestinal disease within the past 3 months\n\nThere is no mention of any gastrointestinal disease, so this criterion is not met.\n\n#10: History of Type I or Type II diabetes in the past 12 months\n\nThere is no mention of any diabetes, so this criterion is not met.\n\n#11: A lifetime history of a suicide attempt or history of any suicidal behavior in the past month\n\nThere is no mention of any suicide attempts or suicidal behavior, so this criterion is not met.\n\n#12: Any clinically significant medical condition that could potentially affect your participation in the study and\/or personal well-being, as judged by the investigator\n\nThe patient has sleep apnea and dissatisfaction with her body shape, which could potentially affect her participation in the study and personal well-being. However, these conditions do not appear to be clinically significant enough to exclude her from the study.\n\nBased on the above analysis, the patient is eligible for the clinical trial.","PROBA":0.9541021696},{"ID":"6892_15-2021_NCT02972671","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is a 70-year-old woman.\n\n#2: The clinical trial is for a device called MiStent, which is used for percutaneous coronary intervention (PCI).\n\n#3: The patient has a history of coronary artery disease and has undergone angioplasty in the past.\n\n#4: The clinical trial is for a non-inferiority study comparing the MiStent to the XIENCE device.\n\nBased on the information provided, the patient is eligible for the clinical trial.","PROBA":0.914839001},{"ID":"6630_15-2021_NCT00630513","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a community-acquired IAI of mild to moderate severity?\nYes, the patient has a community-acquired IAI of mild to moderate severity, as they have a history of diverticulitis with perforation and abscess.\n\n#2: Does the patient require surgical intervention within 24 hours of diagnosis?\nYes, the patient requires surgical intervention within 24 hours of diagnosis, as they have a perforated diverticulitis with abscess.\n\n#3: Is the patient's primary etiology of the infection likely to be infectious?\nYes, the patient's primary etiology of the infection is likely to be infectious, as they have a bacterial infection (E. coli) that caused the perforation and abscess.\n\n#4: Is the patient allergic or hypersensitive to the study antibiotics?\nNo, there is no information in the patient note about any allergies or hypersensitivity to the study antibiotics.\n\n#5: Does the patient have any severe hepatic or renal disease?\nNo, there is no information in the patient note about any severe hepatic or renal disease.\n\nBased on the above, the patient is eligible for the clinical trial.","PROBA":0.934754744},{"ID":"27599_40-2022_NCT01190150","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is a female with heavy menstrual bleeding.\n\n#2: The clinical trial is for adolescent females with heavy menstrual bleeding.\n\n#3: The patient is within the age range of the clinical trial (12-16 years old).\n\n#4: The patient has a history of at least one year of cyclic heavy menstrual bleeding.\n\n#5: The patient meets the other inclusion criteria, such as being generally healthy, not smoking, and using acceptable birth control methods.\n\n#6: The patient does not meet any of the exclusion criteria, such as having a history of abortion in the last 6 months or using vaginal hormone products within 4 weeks prior to screening.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9175879259},{"ID":"14016_30-2021_NCT01420419","TOPIC_YEAR":2021,"RESPONSE":"# No, the patient is not eligible for the clinical trial.\n\nThe patient is a 33-year-old woman with Hashimoto's thyroiditis, and the clinical trial is for breastfeeding women with nipple pain. The patient is not breastfeeding and does not have any issues related to breastfeeding. Therefore, she does not meet the inclusion criteria for the clinical trial.","PROBA":0.9016333707},{"ID":"35823_75-2021_NCT04796246","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Is the patient's disease classified as I-III on the Hoehn & Yahr motor staging scale?\nYes, the patient's disease is classified as mild (Hoehn-Yahr Stage I).\n\n#3: Is the patient over 18 years old?\nYes, the patient is over 18 years old.\n\n#4: Is the patient a resident of Porto Alegre\/RS?\nNo, the patient does not live in Porto Alegre\/RS.\n\n#5: Has the patient signed an informed consent form?\nNo, this information is not provided in the patient note.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9357553024},{"ID":"27622_40-2022_NCT01384331","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is not using the subdermal progestogen-only contraceptive implant.\n\n#2: The patient is experiencing prolonged or frequent vaginal bleeding.\n\n#3: The patient is willing to keep a menstrual diary for 6 months.\n\n#4: The patient does not have any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9117847638},{"ID":"5561_12-2021_NCT04766216","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is not taking warfarin therapy.\n\n#2: The patient has Marfan's syndrome and is planned for mitral valve repair\/replacement surgery.\n\n#3: The clinical trial is for patients taking warfarin therapy.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nC: Irrelevant","PROBA":0.8748103466},{"ID":"30724_65-2021_NCT02230631","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have T1DM or T2DM treated with insulin for more than 12 months?\nYes, the patient has T1DM treated with insulin for more than 12 months.\n\n#2: Is the patient at least 18 years of age at the time of the survey?\nYes, the patient is at least 18 years old.\n\nTherefore, the patient is eligible for the clinical trial.\n\nA: Eligible","PROBA":0.9303441641},{"ID":"5452_12-2021_NCT03390634","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is over 18 years old.\n\nYes, the patient is eligible.\n\n#2: The patient has gastro-oesophageal symptoms according to Montreal criteria.\n\nYes, the patient has symptoms of gastro-oesophageal reflux disease (GORD).\n\n#3: The patient had oesophageal physiology testing at Guy's and St Thomas' NHS Foundation Trust.\n\nNo, the patient did not have oesophageal physiology testing at Guy's and St Thomas' NHS Foundation Trust.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9250876737},{"ID":"35820_75-2021_NCT04781842","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has Parkinson's disease.\n\n#2: Is the patient able to walk without physical assistance?\nNo, the patient is unable to walk without physical assistance.\n\nTherefore, the patient is excluded from the clinical trial.","PROBA":0.9062765567},{"ID":"14087_30-2021_NCT02319538","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient has Hashimoto's thyroiditis.\n\n#2: The patient has been prescribed Levothyroxine.\n\n#3: The patient has not had a total thyroidectomy.\n\n#4: The patient has symptoms that have not been relieved by thyroxine substitution.\n\nBased on these criteria, the patient is eligible for the clinical trial.","PROBA":0.846017093},{"ID":"6958_15-2021_NCT03527706","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have diverticular disease?\nNo, the patient does not have diverticular disease. The patient has pancreatic adenocarcinoma.\n\n#2: Is the patient scheduled for elective sigmoidectomy?\nNo, the patient is not scheduled for elective sigmoidectomy. The patient has pancreatic adenocarcinoma and has already undergone EUS with biopsy.\n\n#3: Does the patient meet the inclusion criteria for the clinical trial?\nNo, the patient does not meet the inclusion criteria for the clinical trial. The clinical trial is for patients with diverticular disease, and the patient has pancreatic adenocarcinoma.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9545432491},{"ID":"35733_75-2021_NCT04054960","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient has Parkinson's disease.\n\nYes, the patient meets the inclusion criterion of having Idiopathic Parkinson's disease (IPD).\n\n#2: The patient is experiencing motor fluctuations.\n\nYes, the patient is experiencing symptoms of bradykinesia, rigidity, tremor, and gait difficulty, which are common problems in the OFF state.\n\n#3: The patient is not wheelchair-bound.\n\nYes, the patient is able to walk independently.\n\n#4: The patient is able to provide informed consent.\n\nYes, the patient is alert and cooperative, and is able to provide informed consent.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9253526763},{"ID":"17358_36-2021_NCT04136093","TOPIC_YEAR":2021,"RESPONSE":"#1: Is the patient a postmenopausal woman?\nYes, the patient is a postmenopausal woman.\n\n#2: Does the patient have central obesity?\nYes, the patient has central obesity.\n\n#3: Does the patient wish to lose weight and have at least one other criterion of metabolic syndrome?\nYes, the patient wishes to lose weight and has at least one other criterion of metabolic syndrome (high blood pressure).\n\n#4: Is the patient willing to follow a specific dietary intervention?\nYes, the patient is willing to follow a specific dietary intervention.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9450530183},{"ID":"16918_36-2021_NCT00489333","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nYes, the patient meets the inclusion criteria. The patient has a BMI of 41.54, which is greater than 30 kg\/m2, and has at least three of the following criteria: fasting blood glucose >100 mg\/dl, blood pressure >130\/85 mm Hg, and total cholesterol >200 mg\/dl.\n\n#2: Does the patient meet any exclusion criteria?\n\nNo, the patient does not meet any exclusion criteria. The patient is not morbidly obese (BMI >40 kg\/m2), is not taking any cholesterol-lowering medications, and does not have any systemic diseases such as AIDS, HIV, active hepatitis, or active malignancy.","PROBA":0.9501020237},{"ID":"24954_53-2021_NCT00377312","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 34-year-old woman from Jordan who has general and non-specific bones and joints pain.\n\nThe clinical trial is for a 7-day continuous parathyroid hormone (PTH) IV infusion to study the effect of PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of urine.\n\nThe patient's age (34) and gender (female) meet the inclusion criteria for the clinical trial.\n\nThe patient's symptoms of general and non-specific bones and joints pain do not meet the exclusion criteria for the clinical trial, which includes cardiac, hypertensive, vascular, renal, pulmonary, endocrine, musculoskeletal, hepatic, hematologic, or malignant diseases.\n\nThe patient's BMI (23) is within the normal range (18.5-30) for the clinical trial.\n\nThe patient has no history of anemia (hematocrit less than 36% in women, less than 40% in men), pregnancy, significant alcohol or drug abuse, or abnormal levels of any of the screening labs, which are all exclusion criteria for the clinical trial.\n\nThe patient is not taking any chronic medications except oral contraceptives and stable doses of thyroid hormone, which are allowed for the clinical trial.\n\nThe patient has not previously received PTH or PTHrP, a related peptide, which is also an exclusion criterion for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9411847164},{"ID":"5483_12-2021_NCT03768115","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient has Marfan's syndrome, which is not listed as an exclusion criterion.\n\n#2: The patient has severe mitral valve prolapse with regurgitation, which is not listed as an exclusion criterion.\n\n#3: The patient has dry eye symptoms, which is listed as an inclusion criterion.\n\n#4: The patient has a history of gestational diabetes mellitus, hypertension during pregnancy, and obesity, which are not listed as exclusion criteria.\n\n#5: The patient has undergone previous surgeries, including laser eye surgery and foot surgery, which are not listed as exclusion criteria.\n\nBased on the information provided, the patient is eligible for the clinical trial.","PROBA":0.9245666333},{"ID":"35513_75-2021_NCT02086825","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient does not have cirrhosis of the liver or renal failure.\n\n#2: The patient does not meet the inclusion criteria for the clinical trial.\n\n#3: The patient does not have any of the exclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nC: Irrelevant","PROBA":0.8678411247},{"ID":"23291_33-2022_NCT01699607","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is not a smoker.\n\n#2: The patient is not a woman.\n\n#3: The patient is not over the age of 55.\n\n#4: The patient does not have any current uncontrolled medical conditions.\n\n#5: The patient does not have a history of neurological or psychiatric disorders.\n\n#6: The patient does not drink more than 21 drinks per week.\n\n#7: The patient does not have a history of marijuana use.\n\n#8: The patient does not suffer from claustrophobia.\n\n#9: The patient does not have any MRI contradictions.\n\nBased on the criteria, the patient is not eligible for the clinical trial.","PROBA":0.9082722703},{"ID":"7102_15-2021_NCT04852406","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a history of cardiovascular or cerebrovascular disease?\n\nNo, the patient does not have a history of cardiovascular or cerebrovascular disease.\n\n#2: Does the patient have a history of atrial fibrillation?\n\nYes, the patient has a history of atrial fibrillation.\n\n#3: Does the patient have a history of venous thromboembolism?\n\nNo, the patient does not have a history of venous thromboembolism.\n\n#4: Does the patient have a history of coronary heart disease?\n\nYes, the patient has a history of coronary heart disease.\n\n#5: Does the patient have a history of stroke or transient ischemic attack?\n\nNo, the patient does not have a history of stroke or transient ischemic attack.\n\n#6: Is the patient scheduled to undergo intra-abdominal surgery?\n\nNo, the patient is not scheduled to undergo intra-abdominal surgery.\n\nBased on the criteria, the patient is not eligible for the clinical trial.","PROBA":0.9577790307},{"ID":"35755_75-2021_NCT04207268","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is at least 20 years old.\nEligible.\n\n#2: The patient has transportation and is willing to travel to the Hershey Community Garden.\nEligible.\n\n#3: The patient has any two health conditions or risk factors for CVD.\nEligible. The patient has hypertension and hypercholesterolemia, which are both risk factors for CVD.\n\n#4: The patient is not currently tending a vegetable garden.\nEligible.\n\n#5: The patient is not pregnant.\nEligible.\n\n#6: The patient has not participated in a past gardening study.\nEligible.\n\n#7: The patient's medical conditions do not preclude safe pursuit of gardening.\nEligible. The patient's Parkinson's disease is not mentioned as a exclusion criterion, so it is assumed that the patient is eligible.\n\n#8: The patient does not have a history of difficulty obtaining blood samples or fear of needles.\nEligible.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9523394858},{"ID":"17263_36-2021_NCT03308487","TOPIC_YEAR":2021,"RESPONSE":"#1: The patient is not pregnant.\n\n#2: The patient is not taking any dietary supplements, including vitamin D.\n\n#3: The patient does not have any preexisting diseases, such as hypertension, cardiac, renal, hepatic, autoimmune, rheumatoid arthritis, or endocrinological disorders, including diabetes, parathyroid disorders, and thyroid disorders.\n\n#4: The patient is not taking any medications that could potentially influence vitamin D metabolism.\n\nBased on these criteria, the patient is not eligible for the clinical trial.","PROBA":0.9176066764},{"ID":"35416_75-2021_NCT01161966","TOPIC_YEAR":2021,"RESPONSE":"# No, the patient is not eligible for the clinical trial. The clinical trial is for the bioequivalence of Zonisamide Capsules, and the patient has Parkinson's disease, which is not related to the study drug. Additionally, the patient is not a healthy adult man or non-child bearing potential woman, as the study requires.","PROBA":0.8729217096},{"ID":"14273_30-2021_NCT04482907","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have multi-nodular goiter?\nYes, the patient has multi-nodular goiter.\n\n#2: Is the patient euthyroid?\nYes, the patient is euthyroid.\n\n#3: Is the patient over the age of 18?\nYes, the patient is over the age of 18.\n\n#4: Does the patient accept the research?\nYes, the patient accepts the research.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9427674042},{"ID":"6772_15-2021_NCT01945125","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have normal renal function?\nNo, the patient has chronic kidney disease (SCr 2.1 in [**3-17**]).\n\n#2: Does the patient have abnormal renal function?\nYes.\n\n#3: Is the patient excluded from the clinical trial due to abnormal renal function?\nYes.\n\nTherefore, the patient is excluded from the clinical trial.","PROBA":0.9136194943},{"ID":"11756_17-2022_NCT02627339","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have any eye diseases?\nNo, the patient does not have any eye diseases.\n\n#2: Is the patient over 10 years old?\nYes, the patient is 67 years old, which is over 10 years old.\n\n#3: Does the patient have visual acuity worse than 20\/40?\nNo, the patient's visual acuity is 50\/100 in both eyes.\n\n#4: Does the patient have cataracts or opacities 2+ or greater?\nNo, the patient does not have cataracts or opacities.\n\n#5: Does the patient have refractive error +6 -6 or greater?\nNo, the patient does not have refractive error.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9525954179},{"ID":"27553_40-2022_NCT00835211","TOPIC_YEAR":2022,"RESPONSE":"#1: The patient is a healthy adult.\n#2: The patient is not pregnant or lactating.\n#3: The patient has not been on a special diet in the past 28 days.\n#4: The patient does not have any clinically significant illness within the past 4 weeks.\n#5: The patient is not taking any prescription drugs.\n#6: The patient has not donated blood or plasma in the past 30 days.\n#7: The patient has not participated in another clinical trial in the past 30 days.\n#8: The patient is not allergic to desmopressin or any other synthetic anti-diuretic hormones.\n#9: The patient does not have a personal or family bleeding disorder.\n\nBased on the information provided, the patient is eligible for the clinical trial.","PROBA":0.9348784926},{"ID":"35758_75-2021_NCT04222088","TOPIC_YEAR":2021,"RESPONSE":"#1 The patient is not a child (age > 6 months to 59 years old).\n\n#2 The patient does not have malaria (Parkinson's disease is not related to malaria).\n\n#3 The patient is not pregnant or breastfeeding (the patient is a male).\n\n#4 The patient does not have any other underlying chronic or severe diseases (Parkinson's disease is not related to malaria).\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.8915603698},{"ID":"30870_65-2021_NCT03605979","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with type 1 diabetes.\n\nYes, the patient meets the inclusion criteria of the clinical trial, which requires patients to be >18 years old and have type 1 diabetes.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.8919408947},{"ID":"35323_75-2021_NCT00282152","TOPIC_YEAR":2021,"RESPONSE":"# Yes, the patient is eligible for the clinical trial.\n\nThe patient meets all the inclusion criteria:\n\n* Clinical diagnosis of probable idiopathic Parkinson's disease\n* Demonstrated response to dopaminergic therapy\n* Hoehn and Yahr stage II when OFF medication\n* No contraindications to surgery\n* Age between 50 and 75 years old\n* Available for follow-up for four years\n\nThe patient does not meet any of the exclusion criteria.","PROBA":0.9471903362}]
